EUCTR2019-004891-20-FR进行中（未招募）1 期
Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL) - REACH
European Organisation for Research and Treatment of Cancer0 个研究点目标入组 100 人开始时间: 2020年12月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Diagnosis of MF-CTCL stage IA or IB at enrolment as per ISCL/EORTC revision to the MF and Sézary syndrome classification [3] and MF stage should have never met the criteria for stage IIA or higher in the patient medical history
- •Availability of tumour biopsy for histological diagnosis of MF-CTCL not older than 12 months. Patients may have had MF for several years.
- •Age = 18
- •ECOG/WHO performance status 0-2
- •Lesions cover less than 80% of BSA
- •Women of child bearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior enrolment
- •WOCBP should use adequate birth control measures, during the study treatment period until 30 days after treatment. (See Appendix H). Male subjects who are partner of WOCBP should use condom during treatment.
- •Female subjects who are breast feeding should discontinue nursing prior to the first application of study treatment and until 30 days after the last study treatment
- •Before patient enrolment, written informed consent must be given according to ICH/GCP, and national/local regulations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Known hypersensitivity to any component of the Chlormethine gel formulation
- •Previous treatment with CL gel
- •Concurrent or planned local or systemic anti-CTCL therapy
- •Prior treatment with antihistamines or narrow band UV-B or PUVA therapy one week before enrolment, or systemic corticosteroids or radiotherapy in the last 4 weeks before enrolment
- •Prior treatment with topical steroids in the patch test area (upper back) one week before enrolment
- •MF or other pathological skin lesions in the patch test area (upper back)
- •Acute flare of atopic dermatitis or other dermatosis in the last 3 weeks
- •Current or recent (past 6 months) history of severe or uncontrolled renal, hepatic, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.
- •A severe disease is defined as a condition which is medically significant although not immediately life-threatening, requires urgent medical intervention, hospitalization or prolongation of hospitalization, is disabling and/or limiting self-care (bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden). All diseases classified as grade 3 or above according to CTCAE version 5.0 are severe conditions.
- •Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, according to the investigator's opinion.
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before enrolment in the trial
研究者
相似试验
尚未招募
不适用
To determine the percentage of raised chloride level in patients who died in Intensive Care Unit of a Tertiary Care Hospital.CTRI/2022/01/039804Md Nezamuddin
招募中
不适用
The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult PatientsMycosis FungoidesNCT06421571National and Kapodistrian University of Athens40
进行中（未招募）
不适用
Clinical Study to Evaluate the Efficacy of Chlorhexidine MouthwashesGingival bleeding and gingivitisMedDRA version: 14.1Level: PTClassification code 10018292Term: GingivitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.1Level: PTClassification code 10018276Term: Gingival bleedingSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-002236-87-GBGlaxoSmithKline Consumer Healthcare
招募中
不适用
Effect of Clomiphene citrate on the function of human fallopian tube secretory cellsCTRI/2020/11/028791ICMR
进行中（未招募）
1 期
Pilot Study to investigate the role of Glutamine in the early protective stress response - Glutamine StudyCritical IllnessEUCTR2006-000576-33-GBSt Helens & Knowsley Hospitals NHS Trust30